SRP product and index pages do not print a sequence, CAS, UNII, molecular formula, or a public COA. Identity below is taken only from opened public registries and primary papers that name DSIP / delta sleep-inducing peptide / emideltide.

One-sentence identity: DSIP (INN emideltide) is a synthetic nonapeptide whose classic sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), first reported from rabbit cerebral-venous dialysate in 1977–1978. It is not melatonin, not GHB / sodium oxybate, not a benzodiazepine or Z-drug, and not an orexin antagonist. Endogenous existence of the free nonapeptide, a receptor, and a precursor gene remain debated. This is a defined sequence, not a tissue extract or undefined mixture.

What the molecule actually is. Schoenenberger & Monnier 1977 (PMID 265572; PMC 430668) name delta-sleep-inducing peptide (DSIP) and print the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (Table 1, MW 849). Schoenenberger et al. 1978 (PMID 568769) repeat that sequence from amino-acid analysis of rabbit cerebral-venous dialysate and state that synthetic DSIP was infused at 6 nmol/kg i.c.v. in rabbits — a historical rabbit-assay condition, not an instruction. PubChem CID 68816 encodes the same nonapeptide as H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH with an L-alpha-aspartyl residue. The 1978 paper states that only the pure alpha-aspartyl peptide is highly active, in contrast to its β-Asp isomer. A research vial labeled “DSIP” is not chemically identified until that sequence (and alpha-Asp vs β-Asp) is confirmed analytically.

Registry chaos that must not be collapsed.

• PubChem CID 3623358 is a same-formula, unspecified-stereo twin (InChIKey ZRZROXNBKJAOKB-UHFFFAOYSA-N). Do not treat it as a second peptide.
• NCATS also has N-Acetyl Emideltide, UNII CL985USD2K, a different record. It is not the SRP listing and is not classic DSIP.
• CAS 62568-57-4 and 69431-45-4 both appear on CID 68816. NCATS marks 62568-57-4 PRIMARY and 69431-45-4 “NO STRUCTURE GIVEN.” Do not invent a reason they differ.
• PubChem MeSH / NCATS prose blocks say DSIP “is found in neurons, peripheral organs, and plasma” and “induces mainly delta sleep in mammals,” including humans. Those sentences were not used as primary findings. The opened 2006 Kovalzon review and the immunoreactivity papers contradict treating endogenous occurrence or human sleep induction as settled.
• ChEMBL “Max Phase Phase 2” is not an NCT and is not a modern efficacy program. ClinicalTrials.gov returned zero studies.

Not printed on SRP pages and therefore not claimed as SRP-verified: sequence, CAS, UNII, formula, alpha-Asp vs β-Asp, or purity numbers. The product page prints a “COA verified” bullet but does not display a public COA. SRP itself is a research-material listing, not a Schoenenberger-lab or clinical lot.

This page is DSIP / emideltide only. Marketplace “sleep peptide” language is a catalog nickname, not a receptor assignment. DSIP is a nine-residue peptide with a printed sequence. It is not an indoleamine, not a four-carbon hydroxy-acid, and not a mapped GABA-A or orexin ligand.

Opened primary papers support only a historical working model. It is not a treatment claim. Observed means a measurement in an opened isolation or EEG paper. Proposed means a hypothesis or analogue observation. Class / adjacent means distinction biology (melatonin, GHB). Not shown means the opened papers did not establish it.

Not shown on an opened page: a cloned DSIP receptor; a precursor gene that is processed to WAGGDASGE; a crystal structure; human PK of an SRP vial; proof that research-market material is the alpha-Asp nonapeptide; a modern, independently replicated human sleep RCT. IUPHAR melatonin ligand 224 and GHB ligand 4711 are distinction biology, not DSIP pharmacology.

Label every row. DSIP ≠ melatonin ≠ GHB ≠ Factor S ≠ KND. Historical sleep papers are listed as what they are — small, old, and concentrated — not as a completed therapeutic program. Historical IV and i.c.v. figures below are study conditions, not instructions for using an SRP research vial, and they are not claims that research-grade material works in people.

Read the “what it did not show” column. Published study designs are historical facts from those papers. They are not a protocol. Human IV figures (typically 25–30 nmol/kg) and the 1978 rabbit i.c.v. 6 nmol/kg condition are study conditions, not instructions for an SRP research vial.

A. Isolation / rabbit EEG

B. Human IV series (n=1 to 18; Schneider-Helmert)

These abstracts report what the authors claimed. They are not modern, independently replicated efficacy trials and they are not ClinicalTrials.gov records. All used intravenous synthetic DSIP, typically 25–30 nmol/kg. That is historical trial-lot exposure, not an SRP-vial instruction.

C. Immunoreactivity / endogenous debate

Adjacent records opened for distinction or logged unused. Graf & Kastin 1984 review (PMID 6145137): early secondary review (MW 849; extra-sleep claims are a catalog of reports, not a receptor). Graf & Kastin 1986 update (PMID 3550726): mechanism “remain to be established.” Pollard & Pomfrett 2001 (PMID 11437870): NCATS cites it; no abstract on the opened Europe PMC page; unused as findings. Monnier et al. 1977 (PMID 862769): isolation-series title; no abstract; unused beyond bibliographic identity. Schoenenberger et al. 1977 (PMID 560681): Pflügers isolation paper X; no abstract; unused beyond bibliographic identity. IUPHAR MT1 287 / melatonin ligand 224 / GHB ligand 4711: distinction table, not DSIP pharmacology.

No ClinicalTrials.gov studies. API v2 queries each returned {"studies":[]}. Do not invent NCTs. 1980s IV series were not registered on the opened CT.gov record.

These are gaps in the opened record. Treating any of them as settled is incorrect. Highlight: 0 NCT; Kovalzon riddle; no receptor; small 1980s IV series; alpha-Asp unknown on the SRP vial.

• No FDA-approved therapeutic use of DSIP / emideltide. NCATS: Investigational; Approval Year Unknown. openFDA: no Drugs@FDA or label hit. Not FDA-approved.
• No ClinicalTrials.gov study. Human efficacy, modern PK, and long-term safety of DSIP are not established. ChEMBL “Phase 2” is not an NCT. CT.gov returned 0 studies.
• Endogenous WAGGDASGE is not an established fact. Isolation was from stimulated-rabbit venous dialysate in 1977–78. Kovalzon 2006: gene, protein, and receptor never isolated; natural occurrence remains obscure. RIA “DSIP-LI” can be a different 77-aa protein (Sillard 1993) or an HPLC shadow (Fischman 1984). Vgontzas 1995 did not support plasma DSIP-LI as a sleep-disorder biomarker.
• A DSIP receptor is not established. IUPHAR has no ligand. Graf 1986 left adrenergic modulation “to be established.” Kovalzon: possible related receptor never isolated.
• Historical sleep claims ≠ proven human sleep drug. Opened human work is 1981–1987, IV, n typically 6–18, largely Schneider-Helmert / Schoenenberger. Abstracts report sleep improvement. There is no opened modern, independently replicated, registered RCT, and no comparison to approved hypnotics on a current label.
• Rabbit i.c.v. delta-EEG is not human oral/subcutaneous sleep architecture. PNAS 1977 is a 94-minute restrained-rabbit ventricular-infusion model.
• Alpha- vs β-aspartyl identity of a research vial is not shown. 1978: only alpha-Asp highly active. SRP does not print sequence or a public COA.
• KND / DIP / Factor S / melatonin / GHB findings are not DSIP findings.
• No opened chronic toxicology, carcinogenicity, or reproductive-tox package for DSIP.
• No opened human dose, bioavailability, or vial-to-brain exposure study that applies to an SRP 5 mg vial. Historical 25–30 nmol/kg IV figures are not instructions.
• Pain, withdrawal, “stress,” antioxidant, and stroke-model papers are not sleep-drug evidence unless a row above actually tested DSIP for that endpoint — and even then they remain small/old or preclinical.
• IUPHAR does not list a DSIP ligand. Receptor assignment is absent, not pending on a Ki table.

Each card is a single opened record. Historical IV and i.c.v. figures are study conditions, not instructions. No NCT is attached because ClinicalTrials.gov returned 0 studies.

DSIP / emideltide is an investigational laboratory research peptide. It is not an FDA-approved drug for human use. This page is educational. It does not provide dosing, reconstitution, administration, or any human-use instructions.

Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application.

Laboratory identity is the first practical issue. Opened papers and PubChem CID 68816 describe the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE / H-WAGGDASGE-OH; CAS 62568-57-4; UNII YN28Z5YZ73; C35H48N10O15; MW 848.8; INN emideltide). The 1978 characterization states that only the pure alpha-aspartyl peptide is highly active versus the β-Asp isomer. CID 3623358 is a same-formula unspecified-stereo twin, not a second peptide. N-acetyl emideltide (UNII CL985USD2K) is a different record. KND (WKGGNASGE) is a different sequence. SRP product pages do not print sequence, CAS, UNII, formula, or a public COA. A method written for melatonin, GHB / sodium oxybate, a benzodiazepine, an orexin antagonist, Factor S, or KND is not automatically valid for this nonapeptide.

Confirm sequence and alpha- vs β-Asp by LC-MS before treating a vial as the literature article. Independently sourced research peptides are not established as equivalent to the 1977 Basel isolation lot or to 1980s clinical IV ampoules. Historical 25–30 nmol/kg IV and 6 nmol/kg i.c.v. figures are study conditions from those papers. They are not a reconstitution scheme and they are not a use guide for an SRP 5 mg / 3 mL research vial. This page does not reproduce NCATS sample-use language as an instruction.

Biological inference has the same problem. The opened record is a 1977–78 rabbit EEG isolation/synthesis, a 1980s human IV series that was never registered on ClinicalTrials.gov (0 studies), immunoreactivity methods with known artifacts, a 1993 cross-reactive 77-aa protein, and a 2006 review that still calls DSIP an unresolved riddle. That is not a completed sleep-drug program and is not evidence for research-market vials.

Sources actually opened for this draft. Do not add PMIDs or NCTs that are not on the allowed list. ClinicalTrials.gov returned 0 studies; no NCT is listed.

Allowed PMID list used on this page: 265572, 568769, 16539679, 6145137, 3550726, 6549071, 6548808, 8375381, 8532601, 6895513, 7028502, 6689058, 3792404, 3622582, 3758119, 3582201, 6548970, 24397026. PMID logged unused (opened, no abstract, unused as findings): 11437870, 862769, 560681. NCT: none. Opened PMC: PMC430668 (Schoenenberger & Monnier 1977 PNAS). No other PMIDs were added. No NCT was invented.

Product links are research materials, not treatment recommendations. Opened SRP page: DSIP 5 mg Sleep Research Peptide Vial; category Brain & Mind Research (store taxonomy, not a clinical indication). Footer: for laboratory research only; not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application. Sequence, CAS, UNII, molecular formula, and a public COA were not printed on the fetched page. Do not confuse with melatonin (MT1/MT2), GHB / sodium oxybate / Xyrem, N-acetyl emideltide (UNII CL985USD2K), KND (WKGGNASGE), or Pappenheimer Factor S.